GCATx is focused on developing small molecule drugs against genetically defined high-value targets critical to disease mechanisms. A number of disease indications, especially within oncology and autoimmune/inflammatory conditions, are driven by activating somatic mutations, providing highly validated targets for therapeutic intervention.

The Company acquires intellectual property from leading academic research institutions covering novel genes that harbor activating (driver) mutations which cause or promote disease in cancer patients.

Our lead program for hematologic malignancies targets a recently identified protein with activating mutations which drive relapse, disease progression and early death.